International Journal of Pharmaceutical Compounding

A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

LEARN MORE

Granisetron Hydrochloride 0.2-mg/mL Oral Suspension

Author(s): Allen Loyd V Jr

Issue: Sep/Oct 2011 - Volume 15, Number 5
View All Articles in Issue

Page(s): 419

Granisetron Hydrochloride 0.2-mg/mL Oral Suspension Page 1

Download in electronic PDF format for $75

Abstract: A formulation for preparing Granisetron Hydrochloride 0.2-mg/mL Oral Suspension. Includes ingredients, method of preparation, discussion, and references for the compounding pharmacist.

Related Keywords: Loyd V. Allen Jr., PhD, RPh, formulation, granisetron hydrochloride, selective type 3 serotonergic blocker, 5-HT3 receptor antagonist, serotonin receptor inhibitor, antiemetic agent, postoperative nausea, vomiting, cancer chemotherapy

Related Categories: CANCER AND AIDS, FORMULATIONS, GASTROENTEROLOGY, DOSAGE FORMS/DRUG CARRIERS, NEUROLOGY

Printer-Friendly Version

Title/Author (Click for Abstract / Details / Purchase)	Issue/Page View/Buy
Related Articles from IJPC
Granisetron Hydrochloride 0.2-mg/mL Oral Suspension Allen Loyd V Jr	Sep/Oct 2011 Pg. 419
Granisetron 1-mg/mL Injection Allen Loyd V Jr	Jan/Feb 2013 Pg. 66
Granisetron Hydrochloride 005 mg/mL in Ora-Sweet and Ora-Plus Allen Loyd V Jr	Nov/Dec 2022 Pg. 513
Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Granisetron Hydrochloride Wu George, Powers Dan, Yeung Stanley, Chen Frank, Neelon Kelly	Jan/Feb 2018 Pg. 86-94
Granisetron 0.05-mg/mL Oral Suspension Allen Loyd V Jr	May/Jun 2006 Pg. 222
Compounding in the Pharmacy Curriculum: Beyond the Basics Hinkle Amanda R, Newton Gail D	May/Jun 2004 Pg. 181-185
Rapid-Dissolve Technology: An Interview With Loyd V. Allen, Jr., PhD, RPh Allen Loyd V Jr	Nov/Dec 2003 Pg. 449-450
Ondansetron Hydrochloride 2-mg/mL Injection Allen Loyd V Jr	Jul/Aug 2012 Pg. 339
Compatibility and Stability of Palonosetron Hydrochloride with Four Neuromuscular Blocking Agents During Simulated Y-Site Administration Trusley Craig, Ben Michel, Kupiec Thomas C, Trissel Lawrence A	Mar/Apr 2008 Pg. 156-160
Basics of Compounding for Cough Allen Loyd V Jr	Nov/Dec 2004 Pg. 462-465
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride Wu George, Yeung Stanley, Chen Frank	Jan/Feb 2017 Pg. 76-82
Compatibility and Stability of Palonosetron Hydrochloride with Gentamicin, Metronidazole, or Vancomycin During Simulated Y-Site Administration Kupiec Thomas C, Ben Michel, Trusley Craig, Trissel Lawrence A	Mar/Apr 2008 Pg. 170-173
Physical and Chemical Stability of Palonosetron Hydrochloride with Topotecan Hydrochloride and Irinotecan Hydrochloride during Simulated Y-Site Administration Trissel Lawrence A, Xu Quanyun A	May/Jun 2005 Pg. 238-241
Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4 Polonini Hudson, da Silva Sharlene Loures, Brandão Marcos Antônio Fernandes, Bauters Tiene, De Moerloose Barbara, Ferreira Anderson de Oliveira	Nov/Dec 2018 Pg. 516-526
Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride Injection and Dexamethasone Sodium Phosphate Injection Wu George, Powers Dan, Yeung Stanley, Chen Frank	Jan/Feb 2018 Pg. 76-85
Compatibility and Stability of Palonosetron Hydrochloride with Lactated Ringer's, Hetastarch in Lactated Electrolyte, and Mannitol Injections During Simulated Y-Site Administration Ben Michel, Kupiec Thomas C, Trusley Craig, Trissel Lawrence A	Sep/Oct 2008 Pg. 460-462
Compounded Pain Formulations: What is the Evidence? Asbill Scott, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso	Jul/Aug 2014 Pg. 278-286
Ondansetron Hydrochloride 0.8 mg/mL in SyrSpend SF pH4 Oral Suspension Allen Loyd V Jr	Jan/Feb 2020 Pg. 60
Compounded Pain Formulations: What is the Evidence? Asbill Scott, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso	Mar/Apr 2024 Pg. 100-109
High-Performance Liquid Chromatographic Method Optimization for Ondansetron Assay in Extemporaneous Topical Gel and in Marketed Products Quamrun Masuda, Mamoon Rashid, Nasheed Shams, Mullins Randy	Nov/Dec 2014 Pg. 520-525
Return to Top